Spots Global Cancer Trial Database for A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
Official Title: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation
Study ID: NCT04438083
Conditions
Interventions
Study Description
Brief Summary: This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.
Detailed Description: The study may enroll approximately 107subjects in total.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site 2, Duarte, California, United States
Research Site 5, Hartford, Connecticut, United States
Research Site 4, Houston, Texas, United States
Research Site 3, Salt Lake City, Utah, United States
Research Site 1, Melbourne, Victoria, Australia
Research Site 6, Toronto, Ontario, Canada
Research Site 7, Amsterdam, North Holland, Netherlands
Contact Details
Name: Alissa Keegan, MD
Affiliation: CRISPR Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
